Vimpat® (lacosamide) – New indication
November 17, 2020 - UCB announced the FDA approval of Vimpat (lacosamide), as adjunctive therapy in the treatment of primary generalized tonic-clonic (PGTC) seizures in patients 4 years of age and older.
Download PDF
